Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing ...

Comprehensive Analysis of the Global Clinical Trials IndustryThe global clinical trials sector is experiencing a significant ...

Perfuze, a leader in next-generation catheter-based technology for the treatment of acute ischemic stroke, today announced ...

Here, the authors report a phase 2 clinical trial investigating immune activation and efficacy of neoadjuvant pembrolizumab administered after one cycle of neo-adjuvant chemotherapy in patients ...

In busy medical clinics, doctors often focus on treating physical problems. Yet mental health risks, like suicide, may go ...

The annual meeting of the American Academy of Neurology was held this year from April 5 to 9 in San Diego. Participants ...

SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson's disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one ...

Octave Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) ...

Hyperfine (HYPR) announced the enrollment of initial patients in the NEURO PMR study. The NEURO PMR study is the first multi-center, ...

Researchers have completed a comprehensive natural history study of SCN8A-related disorders, which represent a spectrum of neurological symptoms. The study, using retrospective clinical information ...

USA: A new study published in Frontiers in Neurology highlights the potential of automatically quantified follow-up imaging biomarkers in predicting clinical outcomes after acute ischemic stroke (AIS) ...

Subjects are expected to stay on a stable dose of ACEi, ARB, SGLT2i, ERAs, and/or MRAs for the duration of the study. * Screening weight of 45 to 150 kg. * Men and women of childbearing potential ...